^
Association details:
| Biomarker: | CXCL10 expression |
|---|---|
| Cancer: | Bladder Cancer |
| Drug Class: | Immunotherapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Predicting prognosis and clinical efficacy of immune checkpoint blockade therapy via interferon-alpha response in muscle-invasive bladder cancer
Published date:
04/04/2023
Excerpt:
Besides, both CXCL10 and LAMP3 expression in the tumor tissues indicated favorable OS in the training cohort (Figure 5D, p = 0.006, p = 0.001, respectively) and validation I cohort (Figure 5E, p = 0.029, p = 0.005, respectively).
DOI:
https://doi.org/10.3389/pore.2023.1611117
